| Completed | Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Ce NCT01959477 | Case Comprehensive Cancer Center | EARLY_Phase 1 |
| Completed | MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma NCT01748721 | Morphotek | Phase 1 |
| Completed | Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors NCT01606878 | Children's Oncology Group | Phase 1 |
| Completed | Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01839916 | University of Chicago | Phase 2 |
| Completed | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem NCT01529827 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Trans NCT01427881 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia NCT01231919 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Canc NCT01053494 | Wake Forest University Health Sciences | N/A |
| Terminated | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS T NCT01088763 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymp NCT00939770 | Children's Oncology Group | Phase 1 / Phase 2 |
| Completed | Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Cent NCT00994500 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating NCT00933985 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With NCT00856388 | Roswell Park Cancer Institute | N/A |
| Completed | Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT01093586 | Case Comprehensive Cancer Center | Phase 2 |
| Completed | Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, NCT00458731 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell NCT00354107 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in T NCT00536601 | Roswell Park Cancer Institute | N/A |
| Completed | A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Bloo NCT00343798 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofe NCT00118352 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or NCT00101205 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease i NCT00105001 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone To NCT00089011 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Mali NCT00078858 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer NCT00049504 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation NCT00040846 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Imm NCT00014235 | Fred Hutchinson Cancer Center | N/A |
| Completed | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporin NCT00006251 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |